Torruella‐Loran I, Ramirez Viña MK, Zapata‐Contreras D, et al; on behalf of the EPIC gastric cancer working group . rs12416605:C\>T in *MIR938* associates with gastric cancer through affecting the regulation of the *CXCL12* chemokine gene. Mol Genet Genomic Med. 2019;7:e832 10.1002/mgg3.832

1. INTRODUCTION {#mgg3832-sec-0005}
===============

Gastric Cancer (GC) or stomach cancer is the fifth most common cancer in the world in terms of incidence and the third leading cause of cancer death in both sexes worldwide (Ferlay et al., [2015](#mgg3832-bib-0016){ref-type="ref"}; Globocan, [2018](#mgg3832-bib-0021){ref-type="ref"}). There are two main locations of gastric adenocarcinoma: proximal (cardia) and distal (noncardia); histologically there are two subtypes of the disease, the intestinal‐type, which presents clearly defined glandular structures, and the undifferentiated diffuse‐type, which consists of individually infiltrating neoplastic cells (Crew & Neugut, [2006](#mgg3832-bib-0013){ref-type="ref"}). GC is a multifactorial disease, whose major risk factors are environmental, such as *Helicobacter pylori* infection, diet or tobacco, as well as genetic (González, Sala, & Rokkas, [2013](#mgg3832-bib-0022){ref-type="ref"}). Several GC susceptibility genes have already been identified by both candidate gene analysis and genome‐wide association studies, among which there are genes involved in immunoinflammatory response, DNA repair, cellular adherence, proliferative processes, mucosa protection, and *Helicobacter pylori\'s* cellular signaling pathways (Loh et al., [2009](#mgg3832-bib-0032){ref-type="ref"}; McLean & El‐Omar, [2014](#mgg3832-bib-0035){ref-type="ref"}; Saeki, Ono, Sakamoto, & Yoshida, [2013](#mgg3832-bib-0041){ref-type="ref"}; Sala et al., [2012](#mgg3832-bib-0042){ref-type="ref"}). A multistep model of carcinogenesis involving the effects of common low penetrance and rare disease‐causing variants is currently accepted for GC (Correa, [1992](#mgg3832-bib-0012){ref-type="ref"}; Fletcher & Houlston, [2010](#mgg3832-bib-0018){ref-type="ref"}). Once the gastric adenocarcinoma has appeared, its prognosis is highly dependent on the progression and metastasis of the tumor, which are intricate processes partially controlled by oncogenes and tumor suppressor genes, whose expression is further regulated by microRNAs (miRNAs) (Esquela‐Kerscher & Slack, [2006](#mgg3832-bib-0015){ref-type="ref"}).

MiRNAs are nonprotein‐coding small RNAs that negatively regulate the gene expression posttranscriptionally (Bartel, [2009](#mgg3832-bib-0006){ref-type="ref"}). The action of miRNAs as gene repressors is performed by means of partial complementarity to miRNA‐binding sites at their target messenger RNAs (mRNAs) resulting in either degradation of the target mRNAs or inhibition of translation (Filipowicz, Bhattacharyya, & Sonenberg, [2008](#mgg3832-bib-0017){ref-type="ref"}). Each mRNA can be repressed by multiple miRNAs, as well as each miRNA is a potential regulator of hundreds of transcripts (Friedman, Farh, Burge, & Bartel, [2009](#mgg3832-bib-0019){ref-type="ref"}; Lewis, Shih, Jones‐Rhoades, Bartel, & Burge, [2003](#mgg3832-bib-0030){ref-type="ref"}) accordingly, it has been estimated that more than half of the total human protein‐coding genes are regulated by miRNAs through complex regulatory networks that control almost every cellular processes, including development, differentiation, proliferation and apoptosis, and having important roles in carcinogenesis (Friedman et al., [2009](#mgg3832-bib-0019){ref-type="ref"}; Kloosterman & Plasterk, [2006](#mgg3832-bib-0029){ref-type="ref"}; ). Aberrant miRNA expression has been related to the diagnosis and stage of many types of cancer and numerous studies validate their prognostic and predictive value (Lu et al., [2005](#mgg3832-bib-0034){ref-type="ref"}; Shen, Stass, & Jiang, [2013](#mgg3832-bib-0043){ref-type="ref"}). In GC various miRNAs have been found differentially expressed between tumor and normal tissues and some of them are associated with the progression and prognosis of GC, being proposed as potential GC biomarkers (Katada et al., [2009](#mgg3832-bib-0025){ref-type="ref"}; Lu et al., [2005](#mgg3832-bib-0034){ref-type="ref"}; Shen et al., [2013](#mgg3832-bib-0043){ref-type="ref"}; Zhou et al., [2015](#mgg3832-bib-0052){ref-type="ref"}).

Genetic association studies have pointed to several miRNA allelic variants as susceptibility factors to GC (Espinosa‐Parrilla et al., [2014](#mgg3832-bib-0014){ref-type="ref"}; Peng et al., [2010](#mgg3832-bib-0038){ref-type="ref"}; Xia et al., [2016](#mgg3832-bib-0046){ref-type="ref"}; Yang et al., [2014](#mgg3832-bib-0048){ref-type="ref"}). Nevertheless, very little is known about the real contribution of these genetic variants to GC pathology. One of the few exceptions is a report showing that the A allele of rs11671784 in the *MIR27A* reduces the expression of the miRNA and is associated with a reduction in the risk of GC (Yang et al., [2014](#mgg3832-bib-0048){ref-type="ref"}). A better understanding of the role of single‐nucleotide variants (SNVs) in miRNAs in the regulation of gastric carcinogenesis could be useful to assess individual susceptibility to GC and to evaluate their functional relevance and potential use as diagnostic and therapy tools.

In this work, we analysed the genetic association between GC and 21 SNVs selected because of their location in functional miRNA regions in a cohort of 365 cases and 1,284 healthy controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We found associations between different GC subtypes and three SNVs: rs3746444:T\>C in the seed of *MIR499A* and mature *MIR499B*, rs12416605:C\>T in the seed of *MIR938*, and rs2114358:T\>C in the precursor sequence of *MIR1206*. Moreover, we performed functional analyses based on miRNA overexpression experiments, transcriptome analyses and target gene‐validation tests, and concluded that rs12416605:T\>C alters the regulatory action of *MIR938* specifically by affecting the regulation of *CXCL12*, a chemokine gene involved in the etiology of GC.

2. MATERIALS AND METHODS {#mgg3832-sec-0006}
========================

2.1. Ethical compliance {#mgg3832-sec-0007}
-----------------------

Patient recruitment, consent, and DNA extraction were carried out as previously described (Riboli et al., [2002](#mgg3832-bib-0039){ref-type="ref"}). Signed informed consent was obtained from all the individuals prior to their participation in the study. The study was approved by ethics committees at the International Agency for Research on Cancer and in each of the EPIC recruitment centers. This study conforms to the Declaration of Helsinki standards for Medical research involving human subjects.

2.2. Subjects {#mgg3832-sec-0008}
-------------

Study subjects were selected from the EPIC cohort according to a nested case--control design aimed at assessing the genetic and environmental risk factors for GC (EurGast study). The EPIC cohort has been extensively presented (Riboli et al., [2002](#mgg3832-bib-0039){ref-type="ref"}). Briefly, it includes 521,457 individuals recruited between 1992 and 2000 in 23 centers from 10 North to South European countries. As previously reported (Espinosa‐Parrilla et al., [2014](#mgg3832-bib-0014){ref-type="ref"}), GC Cases were subjects with adenocarcinoma of the stomach (code C16 of the International Classification of Diseases, 10th Revision) having blood collected and diagnosed during the follow‐up. An independent panel of pathologists confirmed and validated the diagnosis, tumor subsite, and morphology (Carneiro et al., [2007](#mgg3832-bib-0008){ref-type="ref"}). Prevalent tumors, cancer located in gastric stump, as well as tumors other than adenocarcinoma were excluded. For each case, up to four control subjects matched by center, gender, age (±2.5 years), and date of blood collection (±45 days) were randomly selected among cohort members who were alive and free of cancer at the time of diagnosis. The initial study population consisted of 373 GC cases and 1,332 controls. After exclusion of eight cases and 48 controls whose DNA was not amplified or had a genotyping call rate lower than 80%, the final analysis was performed on 365 GC cases and 1,284 matched controls (Espinosa‐Parrilla et al., [2014](#mgg3832-bib-0014){ref-type="ref"}) (Table [1](#mgg3832-tbl-0001){ref-type="table"}). Regarding the localization of tumors, 29.3% were in the cardia or gastroesophageal junction, 49.6% were noncardia, 1.6% presented a mixed localization, and 19.5% were unspecified; as for the histological type, 34.5% were intestinal, 35.1% were diffuse, 2.2% were mixed, and 28.2% were unspecified (Table [1](#mgg3832-tbl-0001){ref-type="table"}).

###### 

Main characteristics of the gastric cancer cases and controls analyzed

                                                        Cases     Controls             
  ---------------------------------------- ------------ --------- ---------- --------- ---------
  Sex                                      Male         214       (58.6%)    759       (59.1%)
  Female                                   151          (41.4%)   525        (40.9%)   
  Anatomical subtype of gastric cancer     Cardia       107       (29.3%)    --        --
  Non‐cardia                               181          (49.6%)   --         --        
  Mixed                                    6            (1.6%)    --         --        
  Unknown                                  71           (19.5%)   --         --        
  Histological subtype of gastric cancer   Intestinal   126       (34.5%)    --        --
  Diffuse                                  128          (35.1%)   --         --        
  Mixed                                    8            (2.2%)    --         --        
  Unknown                                  103          (28.2%)   --         --        

                                  Mean   (Sd)    Mean   (Sd)
  ---------------------------- -- ------ ------- ------ --------
  Age at recruitment (years)      58.4   (7.9)   58.4   (7.69)
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2.3. SNV selection, genotyping, quality control, and data filtering {#mgg3832-sec-0009}
-------------------------------------------------------------------

We selected a panel of 29 non‐monomorphic SNVs located in different functional regions of 30 human miRNAs including all SNVs (dbSNP version 126) located on miRNA genes (miRBase release 13.0) that were known at the moment of the design of the study (Table [S1](#mgg3832-sup-0001){ref-type="supplementary-material"}). Genotyping of these SNVs was included in a panel of 1,536 SNVs described in detail elsewhere (Sala et al., [2012](#mgg3832-bib-0042){ref-type="ref"}). Briefly, genomic DNA was extracted from buffy coat and genotyped at the Spanish National Genotyping Centre (CEGEN) by use of the Illumina BeadStation Platform and GoldenGate Technology (Illumina, San Diego, CA), according to the manufacturer\'s protocols. In addition to the internal genotyping controls, \~5% of the samples (*n* = 100) were genotyped in duplicate with overall agreement of 99.2% (Sala et al., [2012](#mgg3832-bib-0042){ref-type="ref"}). Among the miRNA SNVs selected for the study, eight were excluded from the analysis because of technical genotyping problems (Table [S1](#mgg3832-sup-0001){ref-type="supplementary-material"}). The total number of SNVs successfully genotyped and available for analysis was therefore 21 (Table [2](#mgg3832-tbl-0002){ref-type="table"}). As previously described (Espinosa‐Parrilla et al., [2014](#mgg3832-bib-0014){ref-type="ref"}), deviation from Hardy--Weinberg equilibrium (HWE) was established at *p* \< 10^−4^ (Fisher exact test). According to this criterion, none of the analyzed SNVs deviated from HWE among controls (Table [S1](#mgg3832-sup-0001){ref-type="supplementary-material"}). In all cases significance from deviation was above 0.05 and only one SNP (rs10505168 in *MIR2053*), which was not associated with GC, showed a *p *≤ 0.05 (*p* = 0.008).

###### 

Main characteristics of the miRNA SNVs analyzed

  SNV          miRNA Gene    Chromosome   MAF Controls   MAF Cases   Location    Alleles (major/minor)   Global Fst
  ------------ ------------- ------------ -------------- ----------- ----------- ----------------------- ------------
  rs41291179   *MIR216A*     2            0.053          0.047       precursor   A/T                     0.1068
  rs13186787   *MIR1294*     5            0.002          0.003       precursor   A/G                     0.0188
  rs2910164    *MIR146A*     5            0.240          0.229       seed        C/G                     0.1012
  rs41274239   *MIR96*       7            0.004          0.003       precursor   A/G                     0.0010
  rs2114358    *MIR1206*     8            0.395          0.358       precursor   T/C                     0.0302
  rs10505168   *MIR2053*     8            0.280          0.274       precursor   A/G                     0.0768
  rs11259096   *MIR1265*     10           0.048          0.054       precursor   T/C                     0.2416
  rs17091403   *MIR2110*     10           0.102          0.084       precursor   C/T                     0.031
  rs4919510    *MIR608*      10           0.191          0.178       mature      C/G                     0.1406
  rs12416605   *MIR938*      10           0.258          0.248       seed        C/T                     0.2635
  rs11020790   *MIR548L*     11           0.013          0.007       precursor   C/T                     0.1503
  rs7311975    *MIR1178*     12           0.028          0.026       seed        T/C                     0.3701
  rs11614913   *MIR196A2*    12           0.394          0.410       mature      C/T                     0.2026
  rs2289030    *MIR492*      12           0.058          0.047       precursor   C/G                     0.1107
  rs11844707   *MIR1185‐2*   14           0.001          0.000       precursor   G/A                     0.2655
  rs6505162    *MIR423*      17           0.461          0.452       precursor   A/C                     0.3750
  rs17759989   *MIR633*      17           0.029          0.022       precursor   A/G                     0.0410
  rs895819     *MIR27A*      19           0.320          0.310       precursor   T/C                     0.0412
  rs3746444    *MIR499A*     20           0.192          0.185       seed        T/C                     0.0000
  rs3746444    *MIR499B*     20           0.192          0.185       mature      A/G                     0.0000
  rs4822739    *MIR548J*     22           0.051          0.049       precursor   C/G                     0.0613
  rs5965660    *MIR888*      X            0.187          0.218       precursor   T/G                     NA

Abbreviations: Fst, fixation index; MAF, minor allele frequency.
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2.4. Statistical analyses {#mgg3832-sec-0010}
-------------------------

As previously described, odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated for general GC as well as for its anatomical and histological subtypes using unconditional logistic regression adjusted by the matching variables gender, age, and country using the SNVassoc R package and applying a gene‐based 1000‐permutation test on the log‐additive model to account for multiple testing of the different SNPs analyzed in each miRNA gene region (Espinosa‐Parrilla et al., [2014](#mgg3832-bib-0014){ref-type="ref"}). Other risk factors for GC such as *Helicobacter pylori* infection, smoking and some other lifestyle and dietary factors independent of the genetic variants were not included in the models to retain maximal statistical power. The possibility of population stratification was considered and excluded as previously detailed (Sala et al., [2012](#mgg3832-bib-0042){ref-type="ref"}).

2.5. miRNA cloning {#mgg3832-sec-0011}
------------------

A genomic region of 521 bp including the 83 bp of the precursor molecule of *MIR938* (RefSeq: NR_030634.1) and at least 100 bp at the 5′ and 100 bp at the 3′ flanking regions was amplified from human DNA samples using the forward primer: 5′ cacacacaAGATCTCCAAATCATTCTGGCAGTGA3′ and reverse primer: 5′‐cacacacaCTGCAGTTCATTGCTTGTTGGGATCA‐3′. PCR fragments were cloned into the pmR‐ZsGreen1 vector (Clontech; Mountain View, CA) through *Pst*I and *Bgl*Il restriction sites.

2.6. miRNA transfection experiments {#mgg3832-sec-0012}
-----------------------------------

For RT‐qPCR experiments, HeLa cells were grown as previously described and scaled to 1.8 × 10^5^ cells/well in 12‐well plates (Lopez‐Valenzuela et al., [2012](#mgg3832-bib-0033){ref-type="ref"}). After 24 hr, cells were double‐transfected with Lipofectamine 2000 (Invitrogen; Carlsbad, CA) and 0.75 µg of DNA with the plasmid constructions carrying either one or the other allelic variant of the studied miRNAs, plus a nonhuman miRNA that was used as a control for normalization of transfection. For transcriptome analyses 4.5 × 10**^5^** cells were grown in 6‐well plates and after 24 hr, scaled amount of DNA was single‐transfected with only one of the above described constructs. Transfections were stopped at 24 hr for both RT‐qPCR expression and transcriptome analysis, and 1 ml/well of QIAzol Lysis Reagent (QIAGEN; Venlo, Netherlands) was used for total RNA extraction using miRNeasy Mini Kit (QIAGEN; Venlo, Netherlands). Three and four independent experiments were performed for transcriptome and RT‐qPCR experiments, respectively. Each experiment included three technical replicates in all cases.

2.7. Expression analysis by real‐time quantitative reverse transcription polymerase chain reaction (RT‐qPCR) {#mgg3832-sec-0013}
------------------------------------------------------------------------------------------------------------

MiRNA expression analyses were performed by RT‐qPCR starting from 300 ng of total RNA from transfected cells by using the specific *MIR938* forward primer: 5′‐ CAGTGCCCTTAAAGGTGA‐3′ and *MIR938* reverse primer 5′‐CAGTTTTTTTTTTTTTTTACTGGGT‐3′. Primers design and RT‐qPCR protocol were performed as previously described (Balcells, Cirera, & Busk, [2011](#mgg3832-bib-0005){ref-type="ref"}; Gallego et al., [2016](#mgg3832-bib-0020){ref-type="ref"}), using LightCycler® 480 SYBR Green I Master (Roche Diagnostics; Rotkreuz, Switzerland) following manufacturer\'s protocol. Standard curves were calculated by pooling samples from transfection experiments. Comparison of the expression levels between the two *MIR938* variants was performed from RT templates (30x) by quantifying the relative expression ratio of the studied miRNAs based on the efficiency and on the quantification of cycle deviation (ΔCp) between the two variants, and comparing versus the reference miRNA *MIR25* as previously described (Gallego et al., [2016](#mgg3832-bib-0020){ref-type="ref"}).

2.8. Whole‐Genome expression analyses in HeLa cells using beadchip microarrays {#mgg3832-sec-0014}
------------------------------------------------------------------------------

RNA samples from three independent transfection experiments in HeLa cells were used for microarray expression experiments in Agilent SurePrint G3 Human Gene Expression microarrays (8×60k), starting from 300 ng of total RNA. Data were analyzed using the Array File Maker (AFM) 4.0 software package (Array File Maker; Stanford, CA). We considered genes deregulated when comparing each miRNA allelic variant versus the empty construct and differential regulation between alleles when comparing each miRNA allelic variant versus the other \[nominal *p* \< 0.05 with at least 1.2 fold change (FC)\]. Analyses on the biological functions associated with deregulated genes were performed using the Ingenuity Pathway Analysis software (IPA, [www.ingenuity.com](http://www.ingenuity.com)) and DAVIDGO (<http://david.abcc.ncifcrf.gov/home.jsp>).

2.9. 3′ Untranslated regions (UTR) cloning and luciferase activity assay in HeLa cells {#mgg3832-sec-0015}
--------------------------------------------------------------------------------------

A fragment of 1,106 bp of the 3′ UTR of *CXCL12* (RefSeq: NM_000609.6) was amplified by PCR using forward primer 5′‐acacacgctagcTGTGTTACCTGAAAACACTGTGC‐3′ and reverse primer 5′‐acacactctagaAAGGGACAATTTTTGTTGATGG‐3′ and cloned into PGL4.13 Promega vector containing a Firefly reporter gene, after digestion with *Xba*I enzyme. Co‐transfection experiments have been previously described (Lopez‐Valenzuela et al., [2012](#mgg3832-bib-0033){ref-type="ref"}). Briefly, HeLa cells were seeded at 1.3 × 10^4^ cells per well in 96‐well plates and co‐transfected 24 hr later with the Firefly reporter constructs described above or the empty pGL4.13 vector (24 ng), the Renilla reporter plasmid pGL4.75 (3 ng), and 10 nM miRNA mimic for the mature miRNAs containing either the T or C alleles of rs12416605:C\>T, and the negative control C2 (Dharmacon; Lafayette, CO), using Lipofectamine 2000 (Invitrogen; Carlsbad, CA). Activities of Firefly and Renilla luciferases were measured 24 hr after transfection using Dual‐Glo Luciferase assay system (Promega; Fitchburg, WI). Relative reporter firefly luciferase activity was obtained by normalization to the Renilla luciferase activity. To correct for vector‐dependent unspecific effects, each relative reporter activity was normalized to the empty vector co‐transfected with the corresponding miRNA. Results were then compared with the mean of the C2 negative control. Each experiment was done in triplicate and six independent experiments were performed for each miRNA. Statistical significance was determined using Student\'s *t* test (*p* \< 0.05).

2.10. Target gene prediction analysis {#mgg3832-sec-0016}
-------------------------------------

Potential target genes for *MIR938* allelic variants were predicted using the PITA (Probability of Interaction by Target Accessibility) algorithm (Kertesz, Iovino, Unnerstall, Gaul, & Segal, [2007](#mgg3832-bib-0026){ref-type="ref"}). Minimum accessibility energy score (ΔG) and the energy‐based score for microRNA‐target interactions (ΔΔG) were calculated for all described 3′ UTRs of human RefSeq genes and either the *MIR938* C or T alleles. A transcript was considered as a predicted target when ΔΔG ≤ −8.

3. RESULTS {#mgg3832-sec-0017}
==========

3.1. Association of miRNA SNVs with GC risk and tumor subtype {#mgg3832-sec-0018}
-------------------------------------------------------------

To analyze the possible association between gastric adenocarcinoma and putative functional SNVs located in miRNAs, we genotyped a set of 21 selected SNVs: 15 located in the precursor region, outside of the mature miRNA; two in the mature region, outside the seed miRNA; three in the seed miRNA region; and one SNV, rs3746444:T\>C, that was located in the seed of *MIR499A* and in the mature *MIR499B*, since both miRNA genes overlap in sense and antisense strands of the same genomic region (Table [2](#mgg3832-tbl-0002){ref-type="table"}).

Next, we investigated if there were miRNA SNVs significantly associated with GC and its subtypes in 365 incident GC cases with different histological and adenocarcinoma location phenotypes matched to 1,284 controls from de EPIC cohort (Table [1](#mgg3832-tbl-0001){ref-type="table"}). Results of the association analyses under the log‐additive model are shown in Table [3](#mgg3832-tbl-0003){ref-type="table"}. The strongest association was found for rs2114358:T\>C in the precursor *MIR1206*, which appeared inversely associated with the risk of the non‐cardia localization of the adenocarcinoma (per allele OR = 0.73, 95% CI = 0.58--0.93, *p* = 0.0093) but not for the cardia localization. Additionally, rs3746444:T\>C in the mature *MIR499A* and seed of *MIR499B* was found inversely associated only with the risk of the cardia localization of the adenocarcinoma (per allele OR = 0.64, 95% CI = 0.42--0.98, *p* = 0.0308). As for the histological subtypes, rs12416605:C\>T in the seed of *MIR938*, appeared inversely associated with the risk for the diffuse subtype of GC (per allele OR = 0.7, 95% CI = 0.51--0.97, *p* = 0.0281) but not for the intestinal one (Table [3](#mgg3832-tbl-0003){ref-type="table"}). These results are suggestive of a protective effect against GC for the minor alleles of all three SNVs (C rs2114358, C rs3746444, and T rs12416605).

###### 

Results of the association analyses of miRNA SNVs with general gastric cancer and its histological and anatomical subtypes under the log‐additive model

  SNV              miRNA gene        General GC          Intestinal   Diffuse             Cardia                                         Non‐Cardia                                                                                                   
  ---------------- ----------------- ------------------- ------------ ------------------- ---------------------------------------------- -------------------------- ------------ --------------------------- ------------ --------------------------- ------------
  rs41291179       *MIR216A*         0.87 (0.59--1.28)   0.4657       1.03 (0.58--1.84)   0.9165                                         0.96 (0.53--1.72)          0.8786       0.69 (0.33--1.45)           0.3036       0.98 (0.6--1.61)            0.9343
  rs13186787       *MIR1294*         1.76 (0.32--9.81)   0.5308       0 (0--NA)           0.4122                                         5.38 (0.93--31.27)         0.0937       0 (0--NA)                   0.3872       4.16 (0.73--23.89)          0.1452
  rs2910164        *MIR146A*         0.95 (0.78--1.15)   0.5930       1.11 (0.82--1.49)   0.4988                                         0.8 (0.58--1.11)           0.1723       1.18 (0.85--1.64)           0.3135       0.93 (0.71--1.21)           0.5839
  rs41274239       *MIR96*           0.66 (0.14--3.01)   0.5720       0 (0--NA)           0.1467                                         0.83 (0.1--6.67)           0.8590       0 (0--NA)                   0.2888       0.55 (0.07--4.35)           0.5363
  **rs2114358**    ***MIR1206***     0.85 (0.71--1.01)   0.0600       0.8 (0.61--1.06)    0.1145                                         0.81 (0.62--1.06)          0.1267       1.04 (0.77--1.4)            0.8092       **0.73 (0.58**--**0.93)**   **0.0093**
  rs10505168       *MIR2053*         0.97 (0.81--1.17)   0.7663       0.93 (0.7--1.24)    0.6348                                         0.88 (0.66--1.18)          0.3960       0.83 (0.6--1.14)            0.2486       1.07 (0.84--1.37)           0.5666
  rs11259096       *MIR1265*         1.11 (0.77--1.61)   0.5721       1.36 (0.8--2.33)    0.2728                                         0.87 (0.45--1.69)          0.6764       1.48 (0.83--2.62)           0.1975       0.99 (0.58--1.69)           0.9816
  rs17091403       *MIR2110*         0.81 (0.6--1.09)    0.1505       0.79 (0.49--1.27)   0.3074                                         0.87 (0.55--1.37)          0.5374       0.67 (0.39--1.16)           0.1345       0.85 (0.57--1.26)           0.4017
  rs4919510        *MIR608*          0.92 (0.74--1.15)   0.4724       1.15 (0.83--1.58)   0.4140                                         0.81 (0.56--1.16)          0.2426       1.18 (0.83--1.69)           0.3594       0.87 (0.64--1.17)           0.3449
  **rs12416605**   ***MIR938***      0.95 (0.78--1.15)   0.5733       0.96 (0.71--1.31)   0.8152                                         **0.7 (0.51**--**0.97)**   **0.0281**   0.88 (0.63--1.24)           0.4604       1.07 (0.83--1.38)           0.5896
  rs11020790       *MIR548L*         0.55 (0.21--1.42)   0.1846       0.59 (0.14--2.53)   0.4467                                         0.28 (0.04--2.09)          0.1300       0 (0--NA)                   0.0493       0.6 (0.18--2)               0.3731
  rs7311975        *MIR1178*         0.95 (0.56--1.6)    0.8504       1.33 (0.65--2.75)   0.4514                                         0.86 (0.36--2.03)          0.7197       1.2 (0.53--2.72)            0.6743       0.68 (0.3--1.5)             0.3144
  rs11614913       *MIR196A2*        1.07 (0.9--1.27)    0.4543       1.12 (0.85--1.46)   0.4189                                         1.21 (0.92--1.59)          0.1649       0.9 (0.67--1.21)            0.4830       1.18 (0.93--1.48)           0.1702
  rs2289030        *MIR492*          0.79 (0.54--1.16)   0.2166       0.6 (0.3--1.19)     0.1192                                         0.98 (0.56--1.71)          0.9371       0.62 (0.3--1.29)            0.1739       1.11 (0.7--1.76)            0.6630
  rs11844707       *MIR1185−2*       0 (0--NA)           0.3216       0 (0--NA)           0.4983                                         0 (0--NA)                  0.6115       0 (0--NA)                   0.4749       0 (0--NA)                   0.5279
  rs6505162        *MIR423*          0.96 (0.8--1.15)    0.6746       0.81 (0.6--1.09)    0.1627                                         1.06 (0.8--1.42)           0.6662       1.04 (0.76--1.42)           0.8249       0.88 (0.69--1.13)           0.3195
  rs17759989       *MIR633*          0.71 (0.41--1.25)   0.2212       0.28 (0.07--1.16)   0.0305[a](#mgg3832-note-0003){ref-type="fn"}   0.77 (0.33--1.8)           0.5299       1.07 (0.45--s2.54)          0.8757       0.46 (0.18--1.15)           0.0632
  rs895819         *MIR27A*          0.96 (0.8--1.16)    0.6801       1.08 (0.81--1.45)   0.5919                                         0.92 (0.69--1.25)          0.6048       1.02 (0.74--1.41)           0.8912       0.91 (0.7--1.17)            0.4577
  **rs3746444**    ***MIR499A/B***   0.95 (0.77--1.18)   0.6560       0.95 (0.68--1.32)   0.7490                                         1.07 (0.77--1.48)          0.6977       **0.64 (0.42**--**0.98)**   **0.0308**   1.1 (0.83--1.46)            0.5004
  rs4822739        *MIR548J*         0.96 (0.65--1.41)   0.8297       1.57 (0.93--2.65)   0.1063                                         0.81 (0.43--1.53)          0.5027       1.3 (0.7--2.4)              0.4172       0.77 (0.43--1.35)           0.3401
  rs5965660        *MIR888*          1.12 (0.96--1.32)   0.1625       1.13 (0.88--1.45)   0.3360                                         1.02 (0.77--1.35)          0.8729       1.16 (0.89--1.51)           0.2716       1.24 (1--1.54)              0.0524

Significant associations are shown in bold.

This genetic association is not supported by the confidence interval, which is most likely due to the low frequency of the variant (see Table [S1](#mgg3832-sup-0001){ref-type="supplementary-material"}).
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Analyses by other inheritance models (codominant, dominant, and recessive) indicated that the only association that was stronger with a model different from the log‐additive was that of rs3746444:T\>C with the cardia phenotype, which was better explained by the dominant model (OR = 0.58, 95% CI = 0.36--0.94, *p* = 0.0210).

3.2. rs12416605:C\>T affects the expression of *MIR938* and several gene regulatory pathways {#mgg3832-sec-0019}
--------------------------------------------------------------------------------------------

rs2114358 in *MIR1206*, and rs3746444:T\>C in *MIR499* have already been shown to affect the dosage of the corresponding miRNAs by altering either their biogenesis or stability (Kim, Prokunina‐Olsson, & Chanock, [2012](#mgg3832-bib-0028){ref-type="ref"}; Torruella‐Loran et al., [2016](#mgg3832-bib-0045){ref-type="ref"}). Conversely, no studies have been conducted to analyse the functional effect of rs12416605:C\>T in *MIR938*. We therefore investigated if there were differences in miRNA expression or in gene regulation between both rs12416605:C\>T *MIR938* alleles that could explain their genetic association with GC.

To test the effect of rs12416605:C\>T in *MIR938* expression, we cloned both miRNA alleles and co‐transfected them in HeLa cells (after confirming that these cells had undetectable levels of endogenous *MIR938*) together with a control miRNA for normalization of transfection (Figure [1](#mgg3832-fig-0001){ref-type="fig"}a). After measuring *MIR938* expression by RT‐qPCR, we observed that the rs12416605 C allele was 1.49 times more expressed than the T allele (Student *t* test, *p* \< 0.05) indicating that this variant in *MIR938* may be affecting the final expression of the miRNA (Figure [1](#mgg3832-fig-0001){ref-type="fig"}b).

![Effect of rs12416605:C\>T on *MIR938* expression. (a) Outline of the miRNA co‐transfection experiments in HeLa cells using the pmR‐ZsGreen1 vector (Clontech) containing either one of the two *MIR938* rs12416605 alleles or a nonhuman control miRNA used for normalization of transfection. (b) Box‐plot showing differences in the expression levels (ΔCt), measured by qPCR for the C and T *MIR938* rs12416605 alleles after co‐transfection experiments, related to the control reference miRNA. Each experiment was done in triplicate and four independent experiments were performed. Data reported here are the means ± *SEM* of all experiments performed. A significant reduction between the expression of the C and T alleles was found (*p* \< 0.05, Student\'s *t* test)](MGG3-7-e832-g001){#mgg3832-fig-0001}

In addition to differences in the expression levels between the rs12416605 C and T alleles, this nucleotide substitution could also change the spectrum of miRNA target genes; therefore, we investigated which genes could be regulated by each miRNA allelic variant through miRNA overexpression experiments and transcriptome analyses. After transfection of both miRNA alleles in HeLa cells, we selected those transcripts statistically significant up‐ or downregulated with respect to the control miRNA, using a relaxed cutoff value (*p* \< 0.05, over a 1.2 FC). The *MIR938* C allele deregulated 2,045 transcripts, whereas the T allele deregulated 1,825 transcripts. Among those, 829 were deregulated by both the alleles (this represents 40.5% and 45.5% of the transcripts deregulated by the C and T allele, respectively), indicating that about 50% of the transcripts were exclusively regulated by each rs12416605:C\>T allele. Next, we used Ingenuity Pathway Analysis software to analyse the functions associated with the genes deregulated after overexpression of each *MIR938* allelic variant. Both the alleles presented cancer as their top disease associated with their deregulated genes. Interestingly, variant C but not variant T presented gastrointestinal disease among the top five diseases to which their deregulated genes were associated (Table [S2](#mgg3832-sup-0002){ref-type="supplementary-material"}). According to cancer as the top associated disease and among the top 10 upregulated and downregulated genes, there were several genes that are implicated in the etiology of gastric cancer, such as the protein tyrosine phosphatase nonreceptor type 11 (*PTPN11*) (Liu et al., [2015](#mgg3832-bib-0031){ref-type="ref"}) or the Fibroblast Growth Factor 1 (*FGF1*) (Zhuo et al., [2016](#mgg3832-bib-0053){ref-type="ref"}); (Table [4](#mgg3832-tbl-0004){ref-type="table"}). Remarkably, most of the top 10 downregulated transcripts (8 out of 10) but none of the top 10 upregulated transcripts were common deregulated genes between the two rs12416605:C\>T alleles (Table [4](#mgg3832-tbl-0004){ref-type="table"}).

###### 

Top 10 deregulated genes by *MIR938* rs12416605:C\>T alleles compared to the empty vector control and ordered from the highest to the lowest fold change (FC)

                                *MIR938 C*   *MIR938 T*                                       
  ----------------------------- ------------ ------------ ------------- ---------- ---------- ----------
  Top 10 up‐regulated genes     *TSPAN19*    4.44         3.36E‐02      *HPGDS*    4.39       1.30E‐03
  *C18orf34*                    3.74         5.17E‐03s    *TRPA1*       3.60       8.12E‐04   
  *SLC4A5*                      3.56         4.79E‐03     *SORBS1*      3.51       8.07E‐04   
  *CHD6*                        3.33         4.65E‐02     *PEX5L‐AS2*   3.39       4.82E‐06   
  *BC015129*                    3.14         5.30E‐04     *OR1D5*       3.31       2.58E‐03   
  *IL34*                        3.07         9.48E‐04     *SLC23A2*     3.26       1.46E‐03   
  *OR5B2*                       2.93         3.85E‐03     *FLJ21408*    3.16       2.03E‐07   
  *GRIP1*                       2.77         3.19E‐03     *PRR15L*      3.09       3.36E‐03   
  *SRRM4*                       2.73         2.92E‐02     *RBMS3*       2.99       2.02E‐03   
  *ABCA8*                       2.71         2.00E‐02     *RNF157*      2.95       1.60E‐05   
  Top 10 down‐regulated genes   *NKX2‐8*     −6.65        1.72E‐03      *NKX2‐8*   −5.95      3.02E‐03
  *ZNF730*                      −5.10        2.00E‐03     *ZNF730*      −5.00      2.22E‐03   
  *THPO*                        −4.71        1.45E‐03     *THPO*        −4.68      1.51E‐03   
  *MFSD4*                       −4.27        3.79E‐04     *DNAJC3*      −3.93      2.53E‐03   
  *PTPN11*                      −4.13        8.18E‐03     *HNF1A*       −3.85      7.25E‐03   
  *DPCR1*                       −3.99        1.13E‐02     *MFSD4*       −3.79      9.88E‐04   
  *HNF1A*                       −3.92        6.52E‐03     *FGF1*        −3.78      3.40E‐02   
  *MDM1*                        −3.67        1.02E‐02     *PTPN11*      −3.74      1.35E‐02   
  *C1orf210*                    −3.66        1.91E‐03     *DPCR1*       −3.72      1.58E‐02   
  *CCDC103*                     −3.62        2.32E‐03     *C1orf210*    −3.63      2.00E‐03   

In grey, common deregulated transcripts to both the alleles.
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3.3. The chemokine *CXCL12* is regulated by *MIR938* in an allele‐dependent manner {#mgg3832-sec-0020}
----------------------------------------------------------------------------------

We next investigated if there were cancer‐related genes differentially regulated by the *MIR938* alleles that could be exclusive direct target genes of only one of the rs12416605:C\>T allelic variants of *MIR938*. We used PITA algorithm to predict *MIR938* C and *MIR938* T targets among the whole set of differentially regulated transcripts that were related to cancer according to DAVIDGO (Table [S3](#mgg3832-sup-0003){ref-type="supplementary-material"}). Three GC‐related genes were predicted to be exclusively regulated by one of the *MIR938* allelic variants: the chemokine receptor 5 *CCR5*, the Leptin receptor *LEPR*, and the chemokine *CXCL12* (Table [5](#mgg3832-tbl-0005){ref-type="table"}). Among these genes, the one that presented the highest difference in the PITA prediction between alleles was the *CXCL12* chemokine, which showed a predicted target site for the rs12416605 C allele (ΔΔG = −9.08) whereas any good prediction was found for the T allele (ΔΔG = −0.93) (Table [5](#mgg3832-tbl-0005){ref-type="table"}, Figure [2](#mgg3832-fig-0002){ref-type="fig"}a). These differences between *MIR938* alleles and the fact that *CXCL12* is reported to be involved in GC through its participation in cell migration and invasion (Cheng et al., [2017](#mgg3832-bib-0011){ref-type="ref"}; Izumi et al., [2016](#mgg3832-bib-0024){ref-type="ref"}; Rubie, Kauffels, Kölsch, Glanemann, & Justinger, [2016](#mgg3832-bib-0040){ref-type="ref"}) led us to investigate the possible interaction between *CXCL12* and the rs12416605:C\>T alleles by means of a dual‐luciferase assay in HeLa cells. A luciferase reporter pGL4.13 construct, either empty or carrying the 3′UTR of the *CXCL12*, was co‐transfected with the corresponding miRNA mimic: *MIR938* T, *MIR938* C, or a control miRNA. As shown in Figure [2](#mgg3832-fig-0002){ref-type="fig"}b, a statistically significant reduction in the luciferase activity was observed for the rs12416605 C allele of *MIR938* when co‐transfected with the 3′ UTR of the *CXCL12* compared to both, the control miRNA and the T allelic variant (*p* \< 0.01, Student\'s *t*test). The observed reduction in the luciferase activity would be compatible with a 40% repression of *CXCL12* exclusively by the rs12416605 C allele of *MIR938,* suggesting that differences in the regulation of *CXCL12* between both alleles might be underlying the genetic association of GC with the rs12416605 SNV in *MIR938* and the protective effect found for the T allele against diffuse GC.

###### 

Cancer‐related genes predicted to be differentially regulated by *MIR938* rs12416605:C\>T alleles according to PITA target site predictions

  -----------------------------------------------------------------------------------
  Gene                                                Alleles      Best Pita Score\
                                                                   ΔΔG
  --------------------------------------------------- ------------ ------------------
  *CXCL12 (*Chemokine C‐X‐C motif ligand 12)          **C**        **−9.08**

  T                                                   **−**0.93    

  *CFLAR (CASP8 and FADD‐Like Apoptosis Regulator)*   ***C***      **−15.51**

  **T**                                               **−11.4**    

  *CCR5 (C‐C chemokine receptor 5)*                   C            **−**5.79

  **T**                                               **−12.81**   

  *LEPR (Leptin receptor)*                            C            **−**4.77

  **T**                                               **−11.81**   
  -----------------------------------------------------------------------------------

The best Pita score (energy for microRNA‐target interaction, ΔΔG) for each allele is shown. Relevant Pita score scores are indicated in bold face.

John Wiley & Sons, Ltd

![Allele‐specific regulation of the chemokine *CXCL12* by *MIR938*. (a) Sequence alignment between the *MIR938* rs12416605 C and T alleles and the *CXCL12* mRNA showing the PITA predicted target site and ΔΔG PITA scores for both alleles on this site. (b) Results of the luciferase‐reporter assay testing the interaction between *MIR938* rs12416605 C and T alleles and the 3′UTR of the *CXCL12* in HeLa cells. Ratios of the Firefly and Renilla luciferase luminescence are presented after normalization to the empty plasmid pGL4.13. Each experiment sswas done in triplicate and six independent experiments were performed. Data reported here are the means ± *SEM* of all experiments performed. A significant reduction in the luciferase activity between both the alleles and between the C allele and the control miRNA was found (\*, *p* \< 0.01, Student\'s *t*‐test)](MGG3-7-e832-g002){#mgg3832-fig-0002}

4. DISCUSSION {#mgg3832-sec-0021}
=============

Even though changes in the expression of miRNAs have been largely associated with GC and impaired miRNA expression may be related to genetic variation in their sequences, still there is lack of evidence explaining the real contribution of miRNA genetic variants to GC pathology. In the present study, we evaluated several putative allelic variants in functional miRNA regions as candidate susceptibility factors to GC by means of association studies and demonstrated a possible causative effect for at least one of these variants using a functional approach.

We identified three common genetic variants in miRNA genes that associated with GC. One of them, rs3746444:T\>C in *MIR499*, has largely been reported to be associated with cancer and has further been suggested as having a role in the GC etiology (Ahn et al., [2013](#mgg3832-bib-0001){ref-type="ref"}; Chen, Yang, Chaugai, Wang, & Wang, [2014](#mgg3832-bib-0010){ref-type="ref"}). In the present work, we identified the C allele of this SNV as a protective factor against the cardia GC subtype under the log‐additive and dominant models, which is partially in agreement with a recent meta‐analysis study in which rs3746444:T\>C was reported to be associated with GC in Asian but not European populations (Chen et al., [2014](#mgg3832-bib-0010){ref-type="ref"}). Even though this last study did not find association in Europeans, another study supports our finding by reporting association of this SNV with another cancer type in populations of European origin (Nikolić et al., [2015](#mgg3832-bib-0036){ref-type="ref"}). Furthermore, we have recently shown that the two alleles of rs3746444:T\>C may influence the processing and expression of *MIR499A* and *MIR499B*, which ultimately may be affecting the regulation of their target genes in a dosage and allele‐dependent manner (Torruella‐Loran et al., [2016](#mgg3832-bib-0045){ref-type="ref"}). More importantly, we showed that the T allele of *MIR499A* caused a significant repression of the cadherin *CDH1* and the cell adhesion molecule *CLH1*, which could be associated with a malignant behavior of the T allele and, consequently, with the protective effect found for the C allele against GC.

Another of the SNVs that we found associated with GC was rs2114358:T\>C, in the precursor molecule of *MIR1206*. Even though this miRNA is in the cancer risk loci 8q24.2, this is the first report of a genetic association of *MIR1206* with cancer. Significantly, a previous report demonstrated an effect of rs2114358:T\>C in the biogenesis of the mature miRNA forms (Kim, Prokunina‐Olsson, et al., [2012](#mgg3832-bib-0028){ref-type="ref"}), and several genes involved in GC such us *FGF2* and *TP53INP1* appear as targets of *MIR1206* in miRTarBase. Given the location of this variant in the precursor region outside the mature miRNA molecule, the functional effect of rs2114358:T\>C might be through allele‐specific variation of miRNA expression rather than alteration in the spectrum of target genes.

The third SNV associated with GC was rs12416605:C\>T in the seed of *MIR938*. Interestingly, a previous study reported the association of GC with another SNV (rs2505901) in the *MIR938* primary precursor molecule as well as another variant (rs2275913) in *IL17A*, a *MIR938‐*targeted gene (Arisawa et al., [2012](#mgg3832-bib-0003){ref-type="ref"}). To investigate the possible contribution of rs12416605:C\>T to GC, we analyzed the effect of both the alleles in the expression levels of *MIR938*. Remarkably, statistically significant differences were observed between the expression levels of each miRNA variant: The C variant of *MIR938* was 1.49 times more expressed than the T variant. Besides the alteration in the expression levels of *MIR938*, this *MIR938* variant was also predicted to regulate several gastric cancer‐related genes in an allele‐dependent manner. For instance, the *CASP8* and FADD‐Like Apoptosis Regulator (*CFLAR*) gene has strong ΔΔG PITA scores, particularly for the C rs12416605 allele (−15.51 and −11.4 for the C and T alleles, respectively, Table [5](#mgg3832-tbl-0005){ref-type="table"}). *CFLAR* is a gene that encodes the FLICE‐like inhibitory protein (c‐FLIP) that acts as an inhibitor of the Fas‐mediated apoptosis and helps tumor cells to escape from *TRAIL‐*mediated apoptosis, hence promoting metastasis and tumor progression (Olsson & Zhivotovsky, [2011](#mgg3832-bib-0037){ref-type="ref"}; Zhang et al., [2004](#mgg3832-bib-0049){ref-type="ref"}; Zhou et al., [2004](#mgg3832-bib-0051){ref-type="ref"}). Several SNVs in the *CFLAR* gene have been associated with GC in Chinese populations (Hyland et al., [2004](#mgg3832-bib-0023){ref-type="ref"}) reinforcing a role for *CFLAR* in GC. Moreover, *CFLAR* mRNA and its protein were found highly expressed in gastric adenocarcinomas compared with normal gastric mucosa tissue in patients of Chinese origin stressing the importance of *CFLAR* expression regulation in the pathophysiology of GC (Zhou et al., [2004](#mgg3832-bib-0051){ref-type="ref"}), which may be mediated by *MIR938*. In addition to *CFLAR*, which might be regulated by both allelic variants of *MIR938*, we found at least three other genes that were predicted as exclusive targets of only one of the *MIR938* variants and that are known to play important roles in GC (Table [5](#mgg3832-tbl-0005){ref-type="table"}). For instance, the C‐C chemokine receptor 5 (*CCR5*) and the Leptin receptor (*LEPR*) are related to GC (Chang, Du, Zhao, Ma, & Cao, [2014](#mgg3832-bib-0009){ref-type="ref"}; Kim, Chin, et al., [2012](#mgg3832-bib-0027){ref-type="ref"}; Shi et al., [2014](#mgg3832-bib-0044){ref-type="ref"}), and were predicted to be regulated exclusively by the T allele. Leptin and its receptor are known to play a role in *Helicobacter pylori* infection (Azuma et al., [2001](#mgg3832-bib-0004){ref-type="ref"}), and a polymorphism in *LEPR* has been associated with GC risk in Korean populations (Kim, Chin, et al., [2012](#mgg3832-bib-0027){ref-type="ref"}). Similarly, CCR5 was predicted as targeted solely by the T *MIR938* allele. In this context, the expression of *CCR5* has been found to favor metastasis in GC patients (Cao et al., [2011](#mgg3832-bib-0007){ref-type="ref"}) and thereby, repression of the CCL5/CCR5 axis has been suggested as a possible therapeutic strategy against GC progression (Aldinucci & Casagrande, [2018](#mgg3832-bib-0002){ref-type="ref"}), which would be compatible with a protective effect of the T *MIR938* allele mediated by its putative repression of *CCR5*. Finally, the chemokine *CXCL12* was predicted to be regulated exclusively by the *MIR938* C allelic variant with the best ΔΔG PITA score of −9.08. *CXCL12* has been shown to have a critical role in GC promoting cell migration and invasion, although a controversial participation for *CXCL12* in metastasis has been reported: several authors show that absence of *CXCL12* expression might lead to GC metastasis whereas some others suggest that *CXCL12* overexpression promotes cell invasion (Cheng et al., [2017](#mgg3832-bib-0011){ref-type="ref"}; Izumi et al., [2016](#mgg3832-bib-0024){ref-type="ref"}; Rubie et al., [2016](#mgg3832-bib-0040){ref-type="ref"}; Zhi et al., [2012](#mgg3832-bib-0050){ref-type="ref"}). In this context, the CXCL12/CXCR4 axis has been proposed as a promising therapeutic target for advanced GC (Xue, Mao, Ren, & Chu, [2017](#mgg3832-bib-0047){ref-type="ref"}). The here observed repression of about 40% of this chemokine by the C but not the T allele, together with the increased expression of *MIR938* related to the rs12416605 C allele, might cause an amplified downregulation of *CXCL12* in C carriers that could be associated with a promotion of GC metastasis. This would agree with our finding of the T allele as a protective factor and with the finding of a higher frequency of the T allele in European compared with Asian populations (29% vs. 2%, 1,000 genomes data), which is reflected by a high‐global fixation index (Fst) for this SNV (0.2635 for the global Fst, Table [2](#mgg3832-tbl-0002){ref-type="table"}) and in agreement with Asian populations having a higher predisposition to GC.

In conclusion, we replicated a previously described association of *MIR499* rs3746444:T\>C with GC in European populations and identified two new unreported associations of miRNA SNVs with GC: rs12416605:T\>C in *MIR938* and rs2114358:T\>C in *MIR1206*. We showed a significant difference in *MIR938* expression between rs12416605 alleles and suggested that the protective effect of the T *MIR938* allele against diffuse GC could be mediated by the lack of repression of the chemokine *CXCL12*. These findings strongly suggest a role for *CXCL12* posttranscriptional regulation in the development of GC and as a candidate regulatory pathway for anticancer therapies.
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